Home > Journals > Panminerva Medica > Past Issues > Panminerva Medica 2013 September;55(3) > Panminerva Medica 2013 September;55(3):269-75

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

PANMINERVA MEDICA

A Journal on Internal Medicine


Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,6


eTOC

 

  EXCELLENCES IN DIABETES


Panminerva Medica 2013 September;55(3):269-75

language: English

Closer to ideal insulin action: ultra fast acting insulins

Cengiz E.

Division of Pediatric Endocrinology and Diabetes, Yale School of Medicine, New Haven, CT, USA


PDF  


Mimicking physiologic insulin action has been the main goal of diabetes therapy since the discovery of insulin. The evolution of insulin therapy from animal insulin to recombinant insulin analogs has improved diabetes treatment significantly over the course of years. Nevertheless, the rapid-acting insulin analog pharmacokinetics and pharmacodynamics are still far from replicating physiologic insulin action resulting in poorly controlled after meal blood glucose levels. The slow action of insulin analogs has been a stumbling block for the development artificial pancreas systems that require a fast responding insulin to blood glucose changes. This review explains the rationale behind the undeniable need for ultra-fast acting insulins from a clinical and research perspective and summarizes ongoing and future projects to accelerate insulin action.

top of page

Publication History

Cite this article as

Corresponding author e-mail

eda.cengiz@yale.edu